Item 7.01 Regulation FD Disclosure.
agilon health, inc. (the "Company", "we," "our," and "us") will participate in meetings with the investment community in conjunction with the 41st Annual J.P. Morgan Healthcare Conference, including a presentation on Monday, January 9th at 12:45 PM Eastern Time. During these meetings, the Company's management intends to provide the following updates:
Reaffirm Adjusted EBITDA guidance of $2 million to $7 million for the full year 2022.
Provide preliminary Adjusted EBITDA guidance of $75 million to $90 million for the full year 2023.
Provide preliminary Medicare Advantage membership outlook of above 400,000 members for the year-end 2023, compared to the Company's previous outlook of approximately 390,000 members for the year-end 2023.
We have not reconciled guidance for Adjusted EBITDA to net income (loss), the most comparable GAAP measure, and have not provided forward-looking guidance for net income (loss) because of the uncertainty around certain items that may impact net income (loss) as described below.
Interested investors and other parties may listen to a simultaneous webcast of the presentation on Monday, January 9th by visiting the "Events & Presentations" section of agilon health's investor relations website at https://investors.agilonhealth.com. Replays will be available for on-demand listening shortly after the completion of the presentation.
We define Adjusted EBITDA as net income (loss) adjusted to exclude: (i) income...
Secretary-General says Tehran’s claims are provocative and threaten regional stability Abu Dhabi: Gulf Cooperation Council (GCC) Secretary-General Jassim Mohammed Al Budaiwi has strongly condemned ...